Dry Eye Disease (DED) is a highly prevalent condition that affects the tear film and ocular surface of human or animal eyes resulting in discomfort and impaired vision. Measurement reliability of existing microchip technology for DED is influenced by a range of factors, such as ambient temperature and operator error.Further, the cost of existing systems is substantial and employs relatively expensive single-use consumables, therefore limiting use in clinical practice.Although numerous diagnostic tests are routinely used, clinical diagnosis of DED remains complicated by considerable variability in its presentation and the weak association between traditional tests and patient symptoms.Most dry eye clinical diagnostic tests are poorly standardised which confounds diagnostic accuracy in practice. Although an international approach to diagnose DED has been outlined, DED diagnosis is clinically complex due to significant variability in the self-reported diagnostic approaches for DED among clinicians in multiple demographics. Further, there is a lack of universal consensus in relation to the optimal clinical diagnostic protocol for the condition. This technologyprovides a significant advance in detecting dry eye disease accurately, qualitatively and objectively therefore leading to better treatment regimes.
The technology features a device for evaluating Dry Eye Disease (DED) in a human or animal subject.The technology also relates to methods for diagnosing DED, assessing the severity of DED and diagnosing clinical sub-types of DED and a device customised for performing the diagnostic methods. The method is a simple, rapid and objective method of evaluating DED. It uses a novel approach for assessing tear film integrity for clinical diagnosis of DED. The device uses acoustically-driven microfluidic extension rheometry (ADMiER) to quantify particular properties of human or animal tears.
Factors contributing to growth of Dry Eye Disease include longer life expectancies and extended careers; an expanding middle classin emerging markets with increased access to health care; increased visual demands related to small phones, tablets, and computers; improved diagnostic technologies; and treatment regimens with enhanced effectiveness. Dry eye disease is a ubiquitous, complex, and multifactorial condition, and its effect on dry eye patients ranges from intermittent and annoying discomfort to a serious and chronic vision-threatening disorder. Given the pervasiveness of the condition, demand for dry eye treatments continues to increase worldwide and is spurred by a number of factors. This technology has primary applications in the healthcare and medical industry for: Evaluating and diagnosing the presence of DED in a patient (human or animal) Assessing the severity of DED in a patient (human or animal)
Customer benefits of this technology include: Device which reliably and accurately evaluates DED in a patient Simple, rapid and objective diagnostic method for DED No consumables are required for the device, reducing ongoing costs Better clinical care of DED in ophthalmic practice since DED can be accurately and objectively evaluated.